Sparsentan

Sparsentan, sold under the brand name Filspari, is a medication used for the treatment of primary immunoglobulin A nephropathy. Sparsentan is an endothelin and angiotensin II receptor antagonist. It is taken by mouth.

It was approved for medical use in the United States in February 2023. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Medical uses
Sparsentan is indicated to reduce proteinuria in people with primary immunoglobulin A nephropathy.

Legal status
Sparsentan is approved in the US under accelerated approval based on reduction of proteinuria.

In February 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the granting of a conditional marketing authorization for the medicinal product Filspari, intended for the treatment of adults with primary immunoglobulin A nephropathy (IgAN). The applicant for this medicinal product is Vifor France.